Stay updated on Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial
Sign up to get notified when there's something new on the Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial page.

Latest updates to the Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe study status is updated to terminated due to financial hardships, and results have been posted with dates and linked documents. The prior Active, not recruiting status and earlier submission notes were removed.SummaryDifference2%

- Check14 days agoChange DetectedRevision tag updated to v3.4.2 is now shown. The lapse-in-government-funding notice and the prior Revision: v3.4.1 text were removed.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a site-wide notice about a lapse in government funding, informing users that information may not be up to date and directing them to cc.nih.gov and opm.gov for updates while noting the NIH Clinical Center is open. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedUI/metadata updates include a glossary toggle, a new 'Last Update Submitted that Met QC Criteria' label, and revision/version information in the footer, plus capitalization tweaks. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. No study data or eligibility details were changed.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a top-level Locations section listing Michigan, Missouri, and Ohio as study sites, replacing the prior separate location entries. The page revision also updates from v3.3.2 to v3.3.3.SummaryDifference0.5%

Stay in the know with updates to Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial page.